AB ANALITICA SRL

Their core work

AB Analitica is a Padova-based SME specializing in analytical and biosensing technologies, with a strong focus on molecular detection at the nanoscale. They develop and apply tools for optical single-molecule detection, nanopore-based sensing, and plasmonic nanoparticle systems. More recently, they have expanded into data analysis and AI-driven approaches for precision oncology, bridging their analytical instrumentation expertise with computational methods for clinical decision support.

What they specialise in

How they've shifted over time

In their early H2020 period (2016–2019), AB Analitica focused on wet-lab analytical capabilities — optical single-molecule protein detection (PROSEQO) and molecular characterization of ovarian cancer (HERCULES). From 2021 onward, they shifted toward computational and data-driven work, adding AI-based clinical decision support (DECIDER) alongside continued nanoscale sensing (DNA-FAIRYLIGHTS). This signals a deliberate pivot from pure analytical instrumentation toward hybrid roles combining sensing hardware with software and data intelligence.

AB Analitica is evolving from a purely analytical instrumentation company toward an integrated sensing-plus-AI partner, making them increasingly relevant for projects that need both molecular detection and computational analysis under one roof.

How they like to work

AB Analitica operates exclusively as a consortium participant, never as coordinator, which is typical for a specialized SME contributing domain-specific expertise to larger research efforts. With 30 unique partners across 9 countries in just 4 projects, they work in mid-to-large consortia and show a broad, non-repetitive partner network. This suggests they are adaptable contributors who integrate well into diverse teams rather than anchoring around a fixed set of collaborators.

They have collaborated with 30 distinct partners across 9 countries, indicating broad European reach for a small company. Their network spans both fundamental research groups (FET projects) and clinical consortia (Health projects), giving them an unusually wide contact base for an SME of this size.

What sets them apart

AB Analitica sits at a rare intersection: nanoscale analytical sensing and AI-driven data analysis for biomedical applications. Most biosensing SMEs stay in the hardware lane; AB Analitica's recent move into software engineering and AI for clinical decision-making makes them a dual-capability partner. For consortium builders, they offer a single SME that can contribute both molecular detection know-how and computational data integration — reducing the need for separate specialist partners.

Highlights from their portfolio

• DECIDER
  Their largest-funded project (EUR 388,928), marking a strategic expansion into AI and personalized medicine for overcoming chemotherapy resistance.
• DNA-FAIRYLIGHTS
  Positions them at the frontier of DNA-based data storage using plasmonic nanoparticles — a highly unconventional application of their core sensing expertise.
• PROSEQO
  Demonstrates deep capability in single-molecule optical detection for protein sequencing, a technically demanding analytical challenge.